Abstract

Brain tumours remain a challenging group of diseases and understanding their underlying molecular mechanisms could identify novel therapeutic targets. Previous studies have shown that the CD15 gene, a possible oncogene controlled by the Shh-Gli1 signalling pathway, can be used to identify cancer stem cells in brain tumours. P53 is a key participant in the development and growth of brain tumours, and P53 mutations are common in these tumours. Aim: To study the expression of CD15 and P53 in primary human brain tumour samples. Material and methods: In the study, CD15 and P53 immunohistochemistry was used to examine brain tumour tissues taken from eight individuals. Results: According to the findings, CD15 immunostaining was strong in two cases, weak in five cases, and absent in one case. Four cases showed strong immunostaining for P53, and nuclear atypia was observed in three cases. Conclusion: The study findings highlight the potential role of CD15 and P53 in brain tumour development and progression, and further research could provide new insights into the underlying mechanisms of these tumours and identify novel therapeutic targets.

Description